BSX · 10-Q · 2026Q3 · Full report

Net Income and EPS Performance

BOSTON SCIENTIFIC CORP · 2026-11-02 · Importance 38 · Surprise 30 · From source text

Third-quarter reported net income attributable to Boston Scientific common stockholders declined 22.9% year over year, and diluted EPS fell 20.6% to $0.40. Adjusted net income declined 5.5% to $1.063 billion and adjusted diluted EPS fell 2.6% to $0.73 in the quarter. For the first nine months, reported net income rose 27.1% to $2.830 billion and diluted EPS increased 28.8% to $1.92. The nine-month reported improvement reflected higher sales and a $383 million discrete tax benefit, partly offset by cybersecurity-incident costs.

Key facts

• Nine-month 2026 reported net income attributable to Boston Scientific common stockholders was $2,830 million, up 27.1% year over year. source
• Third-quarter 2026 adjusted net income attributable to Boston Scientific common stockholders was $1,063 million, down 5.5% from $1,124 million. source
• Nine-month 2026 adjusted net income attributable to Boston Scientific common stockholders was $3,527 million, up 4.6% from $3,372 million. source
• Third-quarter 2026 reported net income attributable to Boston Scientific common stockholders decreased 22.9% year over year. source
• Third-quarter 2026 diluted EPS was $0.40, down 20.6% from $0.51; adjusted diluted EPS was $0.73, down 2.6% from $0.75. source
• Nine-month 2026 diluted EPS was $1.92, up 28.8% from $1.49; adjusted diluted EPS was $2.39, up 6.0% from $2.26. source
• Third-quarter 2026 reported net income declined primarily due to cybersecurity-related manufacturing and order-fulfillment disruption, higher supply-chain costs from idle production time, and higher litigation-related net charges. source
• Nine-month 2026 reported net income increased primarily due to higher sales and a first-quarter discrete tax benefit, offset by higher cybersecurity-related costs. source

Impact estimates